Lipella pharmaceuticals announces fda type c meeting for lp-10 for hemorrhagic cystitis

Pittsburgh, pa, april 03, 2024 – lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella,” “our,” “us” or the “company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that the u.s.

LIPO Ratings Summary

LIPO Quant Ranking